3CL蛋白酶抑制剂在抗新型冠状病毒领域的专利申请状况分析  

Analysis of patent application situation of 3CL protease inhibitors in the field of anti-SARS-CoV-2

作　　者：薛姣[1] 曹倩[1] XUE Jiao;CAO Qian(Patent Examination Cooperation Jiangsu Center of the Patent Office,China National Intellectual Property Administration,Suzhou 215163,China)

机构地区：[1]国家知识产权局专利局专利审查协作江苏中心,苏州215163

出　　处：《中国新药杂志》2023年第8期761-767,共7页Chinese Journal of New Drugs

摘　　要：3CL蛋白酶是抗新型冠状病毒(SARS-CoV-2)药物研发的理想靶点,本文对3CL蛋白酶抑制剂在抗SARS-CoV-2领域的专利申请状况进行分析,重点分析了涉及SARS-CoV-23CL蛋白酶抑制剂的专利申请时间分布、重点申请人情况以及重点产品专利申请情况等,反映该类药物全球专利布局格局,揭示我国在该类药物研发上的特点和壁垒,为我国药物研发攻关以及宏观决策提供支撑。结合专利分析结果建议我国申请人基于中医药资源拓展研发思路,同时注重海外专利布局,加快产学研深度融合。3CL protease is an ideal target for the research and development of anti-new coronavirus drugs.In this paper,the patent application situation of 3CL protease inhibitors in the field of anti-SARS-CoV-2 was analyzed.The focuses were put on the application time distribution,profile of patent applicants,and status of key products related to 3CL protease inhibitors,to reflect the global patent application trend,reveal the patent barriers faced by our country in the research and development of the drug,and provide support for the drug research and development.Combined with the results of patent analysis,this paper suggested that Chinese applicants expand their research and development ideas based on traditional Chinese medicine resources,and at the same time pay attention to the layout of overseas patents,and accelerate the in-depth integration of production,education,and research.

关 键 词：3CL蛋白酶抑制剂 新型冠状病毒 帕克洛维 专利分析 

分 类 号：R95[医药卫生—药学]